Day: May 8, 2024

–Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling– –Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical, clinical and scientific expertise– –Company to present this month at upcoming American Association of Clinical Endocrinology annual meeting and GLP-1 Based Therapeutics Summit– –Company to host conference call and webcast today at 8:00 a.m. ET– MIAMI, FL, May 08, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced...

Record Start to the Year for both Q1 Revenue and Gross Margins SANTA ANA, Calif., May 08, 2024 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) today reported results for its first quarter ended March 30, 2024. First Quarter 2024 RecapNet revenue was $190.8 million, an increase of 5.3% over Q1 2023 Net income of $6.8 million, or $0.46 per diluted share, or 3.6% of revenue, up 70 bps year-over-year Non-GAAP adjusted net income of $10.4 million, or $0.70 per diluted share Gross margin of 24.6%, year-over-year growth of 430 bps Adjusted EBITDA of $27.4 million, or 14.4% of revenue, up 170 bps year-over-year“Q1 was an outstanding quarter and a great start to the year for Ducommun, as we grew our topline year-over-year, led by continued strength in Commercial Aerospace at both Boeing and Airbus...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided...

Kojamo plc Stock Exchange Release, 8 May 2024 at 2.00 p.m. EEST Kojamo plc Interim Report 1 January–31 March 2024 Total revenue and net rental income increased, no significant value changes in the investment properties This is a summary of the January–March Interim Report, which is in its entirety attached to this release and can be downloaded from the company’s website at www.kojamo.fi/investors. Unless otherwise stated, the comparison figures in brackets refer to the corresponding period of the previous year. The figures in this Interim Report have not been audited. Summary of January–March 2024Total revenue increased by 4.7 per cent to EUR 113.3 (108.2) million. Net rental income increased by 1.9 per cent to EUR 60.6 (59.5) million. Net rental income was 53.5 (55.0) per cent of total revenue. Result before taxes was EUR 39.3 (24.0)...

YOQNEAM, Israel, May 08, 2024 (GLOBE NEWSWIRE) — MIND C.T.I. LTD. – (NasdaqGM:MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product-based solutions for service providers, enterprise solutions for unified communications analytics and call accounting solutions as well as enterprise messaging solutions, today announced results for its first quarter ended March 31, 2024. The following will summarize our major achievements in the first quarter of 2024, as well as our business. The financial results can be found in the Company News section of our website at http://www.mindcti.com/company/news/ and in our Form 6-K. Financial HighlightsRevenues were $5.8 million, compared with $5.5 million in the first quarter of 2023. Operating income was $1.2 million, or 22% of total revenues, compared...

Insurance Flows and Castlelake Add $75 Billion of AUM Since Quarter End $106 Billion of Dry Powder Available to Invest BROOKFIELD, NEWS, May 08, 2024 (GLOBE NEWSWIRE) — Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) today announced financial results for the quarter ended March 31, 2024. Connor Teskey, President of Brookfield Asset Management stated, “We are off to a strong start in 2024 and are seeing accelerating momentum across our business as transaction activity picks up. We raised $20 billion of capital during the first quarter ($10 billion since our last earnings release), and with more than $100 billion of dry powder to invest, both the diversity of our business mix and our global footprint mean that we remain very well-positioned to capture investment opportunities.” He continued, “We recently completed a $50 billion...

Strong across-the-board year-over-year Q1’24 financial performance driven by yield expansion, transaction growth, unit cost reduction and operating expense discipline Q1’24 operating income loss of $(4.1) million more than halved versus a loss of $(17.1) million in the comparable year-ago period Q1’24 adjusted EBITDA up sharply to $17.7 million vs. $0.4 million in the comparable year-ago period Sustaining a strong balance sheet with cash and marketable securities of $443.6 million to re-invest in the core business organically and inorganically Updated 2024 business outlook reflects sustained strong execution amid macro volatilityCHARLOTTE, N.C., May 08, 2024 (GLOBE NEWSWIRE) — AvidXchange Holdings, Inc. (Nasdaq: AVDX), a leading provider of accounts payable (AP) automation software and payment solutions for middle market businesses...